Hawthorn: Traditional Use, Constituents and Evidence

My nan kept a hawthorn hedge along the back fence of her place outside Stirling, in the Adelaide Hills, and I don't think she thought of it as medicine at all , it was a windbreak, a bird habitat, and in autumn a reliable source of deep-red berries she'd simmer into jelly. I grew up eating that jelly on toast. Only years later, reading through a battered copy of Culpeper's Complete Herbal on a rainy Saturday, did I realise I'd been casually consuming one of Europe's most consistently documented botanical subjects for most of my childhood.

That's the thing about hawthorn. It tends to be quietly everywhere before you notice it.

What we mean by hawthorn

The name "hawthorn" covers a sprawling genus: Crataegus, with several hundred species distributed across the Northern Hemisphere. The two most studied in phytomedicine research are Crataegus monogyna (the single-seeded hawthorn, common across Europe and naturalised widely in southern Australia) and Crataegus laevigata (the Midland hawthorn, sometimes listed as C. oxyacantha in older literature). Most standardised preparations in the scientific literature use leaf and flower rather than the berry, though traditional use spanned all three plant parts.

In Australia, Crataegus monogyna is well-established in cooler, wetter regions , you'll find it hedging old farmland across the Adelaide Hills and the Victorian ranges , and in some states it is listed as an environmental weed. Worth keeping that tension in mind: botanically significant, ecologically complicated.

A very long paper trail

Hawthorn appears in European medical texts going back at least to the first century CE, with Dioscorides noting the plant, and again in medieval herbals from Germany and Britain. By the 19th century, Irish physician Dr Green of Ennis was reportedly using it in clinical practice, and from the early 20th century it began appearing in pharmacopoeial references on both sides of the Atlantic.

Traditional Chinese medicine has its own hawthorn history, largely involving Crataegus pinnatifida (shān zhā), which is a different species but closely related pharmacologically; its constituents overlap considerably. The dried fruit of C. pinnatifida remains listed in the Chinese Pharmacopoeia today.

What's consistent across these traditions is that hawthorn was almost universally associated with the heart and circulatory system, a pattern that has made it one of the more obviously testable plants in modern phytomedicine research, since the proposed traditional use maps onto endpoints that clinical trials can actually measure.

Key constituents

The chemistry is genuinely interesting. Hawthorn leaf and flower preparations are typically characterised by two major compound classes.

Oligomeric proanthocyanidins (OPCs) are condensed tannins, polyphenolic structures formed from flavan-3-ol units. They're present at relatively high concentrations in hawthorn, and standardised extracts are often benchmarked to OPC content (commonly expressed as percentage epicatechin). OPCs are potent antioxidants in vitro; what that translates to in vivo is a much more complicated question, given the bioavailability challenges of larger polyphenolic molecules and the substantial influence of first-pass metabolism in their oral absorption.

Flavonoids, particularly vitexin-2″-O-rhamnoside and hyperoside, are the other major marker class and appear in higher concentrations in the leaf and flower fraction than in the berry. Some European standardised extracts are characterised by both OPC content and total flavonoid content simultaneously.

The berries (haws) contain a different profile; higher in anthocyanins and pectin, lower in vitexin derivatives, which partly explains why the traditional whole-plant uses and the modern research extracts don't always describe the same thing. It's a point worth flagging because the gap between "hawthorn" in popular use and the specific preparations studied in trials is often quite wide.

Minor constituents include triterpene acids (ursolic, oleanolic, and crataegolic acid), amines, and various phenolic acids. Hawthorn doesn't contain terpenes in the same sense as aromatic plants, there's no significant essential oil fraction in the leaf and flower; though the berry does carry small amounts of volatile compounds contributing to flavour.

What the research has actually looked at

The majority of human trial data on hawthorn has focused on standardised leaf-flower extracts, particularly a well-characterised preparation (a specific dry extract standardised to OPC and flavonoid content) that has been studied in several European multicentre trials. I won't name the preparation, the research should stand separately from commercial products, but the underlying pharmacology has been explored across a reasonable number of controlled studies.

The largest randomised controlled trial in this space, the SPICE trial published in 2008 (Holubarsch et al., European Journal of Heart Failure), enrolled over 2,600 patients across multiple countries and ran for 24 months. It's the kind of trial scale that phytomedicine rarely achieves. The results were mixed: the primary composite endpoint was not met in the overall population, though subgroup analyses suggested possible differential outcomes in specific patient groups. The investigators themselves were measured about what the data could and couldn't support.

Honestly, that's a fair summary of where hawthorn research sits overall: promising preliminary and in vitro data, some positive smaller clinical studies, one large trial that couldn't confirm the primary hypothesis. The mechanistic proposals; including effects on phosphodiesterase inhibition and ion channel activity observed in cell and animal models, are scientifically plausible. But plausible mechanisms and controlled clinical outcomes are different things, and I'd rather flag that gap clearly than paper over it.

Systematic reviews, including a Cochrane review by Pittler, Guo and Ernst (2008, updated since), have generally concluded that the evidence from smaller trials shows some positive signals but that the data are insufficient to draw firm conclusions about clinical efficacy. The Cochrane review is accessible via PubMed and worth reading in full for anyone wanting the granular picture.

Australian regulatory context

In Australia, hawthorn preparations sold for human consumption would typically be listed or registered on the Australian Register of Therapeutic Goods (ARTG). Most hawthorn products on the Australian market are ARTG-listed complementary medicines, a regulatory category that involves TGA assessment of safety and manufacturing quality, but not independent pre-market verification of efficacy claims. The TGA's framework for listed medicines (AUST L number products) permits certain low-level "health maintenance" indications from a permitted indications list, but does not allow the kind of specific therapeutic claims that would require a higher level of evidence.

That distinction matters. A product can carry an AUST L number and appear legitimate; which in terms of manufacturing quality it may well be, without the listing process having evaluated whether its active dose of hawthorn extract actually does anything measurable in humans. Good Manufacturing Practice standards govern the production side; evidence standards govern the claims side, and they're separate questions.

The TGA's permitted indications list for hawthorn-containing listed medicines is specific and limited. Anyone reviewing the regulatory framework in detail should consult the TGA's Ingredient Information document for Crataegus species directly at tga.gov.au, as the permitted indications are updated periodically.

There are no specific scheduling controls on hawthorn in the Poisons Standard, it is not a scheduled substance, and standard retail sale is permitted. This contrasts with plants like kava (Piper methysticum), which carries specific Australian import quantity restrictions under a separate regulatory instrument. Hawthorn doesn't attract that kind of oversight; the regulatory questions are primarily about claims, not access.

Constituents in context: what the chemistry doesn't tell you

One thing I find consistently underappreciated in discussions of botanical chemistry is how much the standardisation question complicates lay comparisons of products. Saying "hawthorn" doesn't specify which part of the plant, at what extraction ratio, standardised to which markers, at what daily dose. A 300 mg capsule of a 4:1 berry extract and a 450 mg capsule of a leaf-flower dry extract standardised to 18.75% OPC are not the same thing, even if both say "hawthorn" on the label. The trial evidence, such as it is, applies to specific preparations at specific doses; and the gap between that and the general supplement market is real.

The pharmacokinetics of the major flavonoid markers have been studied to some degree in humans, with vitexin glycosides showing relatively modest oral bioavailability in pharmacokinetic studies, partially modified by the gut microbiome's enzymatic activity. This is consistent with the broader pattern seen across polyphenol research and is worth bearing in mind when extrapolating from in vitro antioxidant data to in vivo outcomes.

Sources

• Hawthorn extract for treating chronic heart failure, Cochrane Library (Pittler, Guo & Ernst)
• The clinical and experimental evidence for Crataegus, National Center for Biotechnology Information (NCBI)
• Listed medicines permitted indications; Therapeutic Goods Administration (TGA)
• Phytochemistry and pharmacology of Crataegus species, NCBI/PMC

, Naomi Ellison, Botanical & phytomedicine writer

]]>